INTRODUCTION
============

Chylous ascites is a relatively rare form of ascites resulting in the accumulation of lymph in the abdominal cavity. It is characterized by a milky ascitic liquid with an elevated concentration of triglycerides (\>200 mg/dl)^\[[@b1-871-1-5294-1-10-20180328]\]^. Although there have been no recent large epidemiological studies, it is generally believed that its incidence has increased due to the longer survival of patients with cancer and more aggressive abdominal and cardiothoracic interventions.

The main pathophysiological mechanisms postulated for this condition are: (a) obstruction of the flow of lymph caused by external pressure leading to leakage from dilated subserosal lymphatic channels into the peritoneal cavity; (b) lymph exuding through the walls of dilated retroperitoneal vessels without valves, which leak fluid through a fistula into the peritoneal cavity, as in congenital lymphangiectasia; and (c) traumatic obstruction of the thoracic duct^\[[@b2-871-1-5294-1-10-20180328]\]^.

We describe a case of lymphoproliferative disease presenting as chylous ascites.

CASE REPORT
===========

An 87-year-old man presented with abdominal distension, peripheral oedema and constitutional symptoms of fatigue, anorexia and involuntary weight loss (12.7%). His medical history was positive for hypertension and alcohol consumption of 36 g per day for the last 40 years. There was a positive family history of gastrointestinal cancer.

On physical examination, the patient had obvious ascites (grade III) and lower extremity oedema. Vital signs were normal. There was no jaundice or scleral icterus and also no signs of chronic liver disease, palmar erythema, enlarged parotids or gynecomastia. The abdomen was distended with bulging flanks, a fluid wave, shifting dullness and signs of hepatofugal collateral circulation. No abdominal organomegaly was detected. Cardiovascular and pulmonary examinations were normal. Pitting oedema was present in both legs up to the thighs. Two enlarged axillary lymph nodes were also detected. Initial investigation revealed a widened mediastinum on chest X-ray ([Fig. 1](#f1-871-1-5294-1-10-20180328){ref-type="fig"}).

Initial laboratory tests showed a normal haemogram and blood smear, erythrocyte sedimentation rate of 50 mm/hour (normal values: 0--20), C-reactive protein of 5.74 mg/dl, lactate dehydrogenase (LDH) of 370 IU/l (normal values: 135--225) and triglycerides of 88 mg/dl. Serum protein electrophoresis showed: albumin 3.02 (normal values: 3.9--5.1 mg/dl), alpha 1 0.23 g/dl, alpha 2 0.86 g/dl, beta (pt) 0.54 g/dl, and gamma 1.66 g/dl. Immunoglobulin G was elevated (1640.0 mg/dl), but immunoglobulins A and M were normal ([Table 1](#t1-871-1-5294-1-10-20180328){ref-type="table"}).

Abdominal paracentesis revealed a milky peritoneal fluid with albumin of 1.1 g/dl and a serum-ascites albumin gradient of 2.1 g/dl. The ascitic fluid contained 1461 leucocytes/μl (79% mononuclear cells), triglycerides 2298 mg/dl, glucose 85 mg/dl, adenosine deaminase (ADA) 34 IU/l and LDH 174 IU/l. Culture was negative as was cytological examination for malignant cells. Further testing revealed an elevated B2-microglobulin of 11.7 mg/l (normal values 0.8--2.2). Viral serologies (HIV, HCV, HBV) were also negative. In the urinalysis no pathological alteration was found, except for low grade proteinuria. Serum electroimmunofixation was positive for IgM lambda.

Subsequent investigation with computerized tomography (CT) revealed multiple thoracic and abdominal lymphadenopathies forming large conglomerates, the largest abdominal mass having a diameter of 20 cm ([Fig. 2](#f2-871-1-5294-1-10-20180328){ref-type="fig"}).

The patient began oral furosemide 40 mg and spironolactone 100 mg with ascites volume reduction and better symptom control.

Excisional biopsy of the axillary adenopathy revealed mantle cell lymphoma with a diffuse architectural pattern, classic type with a proliferative index of 20% ([Fig. 3](#f3-871-1-5294-1-10-20180328){ref-type="fig"}). Bone marrow and gastrointestinal involvement was not investigated since treatment would not be effective. Stage III/IV mantle cell non-Hodgkin lymphoma was diagnosed and after discussing the goals of treatment, palliative chemotherapy according the PEPC protocol (prednisolone 20 mg once a day (OD), cyclophosphamide 50 mg OD, etoposide 50 mg OD and procarbazine 50 mg OD). The patient died from pneumonia 1 month after beginning treatment.

DISCUSSION
==========

The standard treatment for chylous ascites has not yet been established. However, the best results have been obtained by treating the underlying cause (in this specific case a lymphoma). For patients in whom the cause is not found or who do not respond to treatment of the underlying cause, nutritional therapy with a high-protein and low-fat diet with medium-chain triglycerides is recommended. Other approaches include frequent paracentesis, surgery (using sclerosing agents and suture ligation of the thoracic duct) or peritoneovenous shunting^\[[@b3-871-1-5294-1-10-20180328]\]^. Our patient had concomitant portal hypertension, the underlying mechanism being pre-hepatic due to extrinsic compression of portal circulation. Although he responded favourably to diuretics, he died due to a nosocomial pneumonia. This case highlights the fact that although most cases of chylous ascites are related to trauma, some may be due to other causes such as lymphoproliferative diseases, pancreatitis^\[[@b2-871-1-5294-1-10-20180328]\]^ or retroperitoneal fibrosis^\[[@b4-871-1-5294-1-10-20180328]\]^.

**Conflicts of Interests:** The Authors declare that there are no competing interests.
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![Abdominal CT scan showing the abdominal conglomerate](871_Fig2){#f2-871-1-5294-1-10-20180328}

![Histology of the axillary lymph node showing a diffuse architectural pattern and varying cytology with a proliferative index of 20%](871_Fig3){#f3-871-1-5294-1-10-20180328}

###### 

Analytic diagnostic workup and evolution

  Analytic parameters                           Admission     Day 2         Day 3         Day 9           Normal values
  --------------------------------------------- ------------- ------------- ------------- --------------- ----------------
  **Haemoglobin (g/dl)**                        *12.32*       *11.3*        *11.3*        *11.5*          **13--18**
  **Erythrocytes (×10^12^)**                    *4.05*        *3.67*        *3.67*        *3.78*          **4.4--5.9**
  **Haematocrit (%)**                           *37.1*        *33.1*        *33.1*        *34.8*          **40--52**
  **Leucocytes (×10^3^)**                       *8.55*        *6.09*        *5.60*        *6.82*          **3.8--10.6**
  **Neutrophils (%)**                           *78.5*        *73.6*        *71.1*        *71.3*          **1.3--8.8**
  **Lymphocytes (×10^3^/%)**                    *1.13/13.2*   *0.95/15.6*   *0.84/15.0*   *1.25/18.3*     **1.0--4.8**
  **Platelets (×10^3^/μl)**                     *296*         *280*         *296*         *360*           **150--440**
  **Sedimentation velocity (mm/s)**             *--*          *50*          *--*          *--*            **0--15**
  **Glucose (mg/dl)**                           *86*          *76*          *--*          *--*            **60--100**
  **Creatinine (mg/dl)**                        *1.05*        *1.33*        *1.49*        *1.53*          **0.67--1.17**
  **Urea (mg/dl)**                              *49*          *51*          *49*          *95*            **17--50**
  **Sodium (mmol/l)**                           *135*         *134*         *134*         *131*           **136--145**
  **Potassium (mmol/l)**                        *5.14*        *5.54*        *5.19*        *4.94*          **3.5--5.0**
  **Chloride (mmol/l)**                         *49*          *51*          *91*          *87.0*          **17--50**
  **Calcium (mg/dl)**                           *--*          *8.2*         *--*          *--*            **8.4--9.7**
  **Uric acid (mg/dl)**                         *--*          *--*          *8.40*        *--*            **0.2--5.7**
  **Total bilirrubin (mg/dl)**                  *0.46*        *0.41*        *--*          *0.34*          **0.1--1.1**
  **Lactacte dehydrogenase (U/l)**              *370*         *300*         *258*         *273*           **135--225**
  **Aspartate aminotransferase (AST -- U/l)**   *33*          *27*          *26*          *36*            **4--33**
  **Alanine aminotransferase (ALT -- U/l)**     *11*          *11*          *12*          *21*            **4--50**
  **Gamma glutamyl transferase (GGT - U/l)**    *25*          *19*          *19*          *26*            **5--61**
  **Alkaline phosphatase (U/l)**                *93*          *87*          *83*          *91*            **40--129**
  **Total proteins (g/dl)**                     *--*          *6.3*         *6.5*         *--*            **6.4--8.3**
  **Albumin (g/dl)**                            *3.3*         *--*          *3.1*         *--*            **3.4--4.8**
  **Triglycerides (mg/dl)**                     *98*          *88*          *100*         *--*            **\<200**
  **C reactive protein (CRP -- mg/dl)**         *5.13*        *5.74*        *4.01*        *3.69*          **0--0.5**
  **B 12 vitamin (pg/ml)**                      *--*          *--*          *304.7*       *--*            **197--771**
  **Folic acid (ng/ml)**                        *--*          *--*          *1.9*         *--*            **4.6--18.7**
  **Antinuclear antibodies (ANA)**              *--*          *\<1/160*     *--*          *--*            **\<1/160**
  **B2-microglobulin (mg/l)**                   *-*           *11.7*        *--*          *--*            **0.8--2.2**
  **Immunoglobulin G**                          *1640*        *--*          *2030*        **680--1450**   
  **Immunoglobulin A**                          *--*          *389*         *--*          *427*           **83--407**
  **Immunoglobulin M**                          *--*          *115*         *--*          *131*           **34--214**
  **Kappa chain**                               *--*          *--*          *--*          *48*            **200--440**
  **Lambda chain**                              *--*          *--*          *--*          *344*           **110--240**
  **Kappa/lambda relationship**                 *--*          *--*          *--*          *1.4*           **1.35--2.70**
